Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
In this trial, we plan to evaluate further the role of arsenic trioxide in the treatment of
patients with refractory multiple myeloma. Arsenic trioxide will be used in combination with
thalidomide. Although both drugs have a similar mechanism of action, it is likely that the
mechanisms may be additive or synergistic. Since neither drug produces much myelosuppression,
this combination regimen should be tolerable in patients with compromised marrow function due
to involvement with myeloma and/or previous cytotoxic chemotherapy